{"entity":{"id":"simron-singh","kind":"person","name":"Simron Singh","aka":[],"tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.","summary":"Simron Singh was principal investigator of NETTER-2, which showed first-line 177Lu-DOTATATE plus octreotide dramatically improves progression-free survival over high-dose octreotide in grade 2-3 gastroenteropancreatic neuroendocrine tumours, extending radioligand therapy to newly diagnosed patients. He has led Canadian and international NET guidelines and studies of NET epidemiology and patient-reported outcomes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"tags":["neuroendocrine","radioligand","canada"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":["sunnybrook-odette"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre","institutionId":"sunnybrook-odette","specialisms":["Neuroendocrine tumours","Radioligand therapy","Health services research","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"papers":[{"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00701-3"},{"title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors","journal":"Journal of Thoracic Oncology","year":2020,"doi":"10.1016/j.jtho.2020.06.021"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},"route":"/people/simron-singh/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"institution":[{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/"}],"paper":[{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"}],"journal":[{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/"}]}}